Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lenalidomide - Celgene Corporation

Drug Profile

Lenalidomide - Celgene Corporation

Alternative Names: CC-5013; CDC-501; CDC-5013; ENMD-0997; IMiD-1; IMiD-3; Ladevina; Revimid™; REVLIMID

Latest Information Update: 19 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Celgene Corporation
  • Developer Baylor College of Medicine; Celgene Corporation; Dana-Farber Cancer Institute; Gilead Sciences; Groupe dEtude des Lymphomes de lAdulte; H. Lee Moffitt Cancer Center and Research Institute; Helsinki University Central Hospital; Indiana University School of Medicine; IRCCS San Raffaele; Massachusetts General Hospital; National Cancer Institute (USA); Nordic MDS Study Group; Novartis; Ohio State University Comprehensive Cancer Center; Peking Union Medical College Hospital; Roche; Roswell Park Cancer Institute; Royal Marsden NHS Foundation Trust; SCRI Development Innovations; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; University of California, Davis; University of Florida; University of Wuerzburg; Washington University School of Medicine
  • Class 2 ring heterocyclic compounds; Antineoplastics; Imides; Isoindoles; Piperidones; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Cell proliferation inhibitors; Immunomodulators; Interleukin 6 inhibitors; Natural killer cell stimulants; Natural killer T cell stimulants; T lymphocyte stimulants; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; Myelodysplastic syndromes; Chronic lymphocytic leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Mantle-cell lymphoma; Multiple myeloma; Myelodysplastic syndromes
  • Registered Adult T-cell leukaemia-lymphoma
  • Preregistration Non-Hodgkin's lymphoma
  • Phase III Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma
  • Phase II Acute myeloid leukaemia; Histiocytosis; Hodgkin's disease; Myelofibrosis; POEMS syndrome; Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase I/II Non-small cell lung cancer
  • Phase I Chronic myeloid leukaemia
  • No development reported Cancer; Eye neoplasms; Glioblastoma; Peripheral T-cell lymphoma; Prostate cancer; Solid tumours
  • Discontinued Colorectal cancer; Heart failure; Inflammation; Liver cancer; Malignant melanoma

Most Recent Events

  • 31 Jan 2019 The US FDA plans action date for supplemental NDA submitted based on AUGMENT™ trial for Non Hodgkin's Lymphoma in the second half of 2019
  • 21 Jan 2019 Phase II development is ongoing in USA (NCT00352794)
  • 07 Jan 2019 Celgene expects approval of lenalidomide in combination with bortezomib and dexamethasone for Multiple myeloma (Newly diagnosed)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top